
Opinion|Videos|January 19, 2026
Other Standout Data in PTCL From ASH 2025
Author(s)Francine Foss, MD, Matthew Lunning, DO, FACP
Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss other key data from ASH 2025 and ongoing research to watch in peripheral T-cell lymphoma.
Advertisement
Episodes in this series

Francine Foss, MD, and Matthew Lunning, DO, FACP, highlight additional notable peripheral T-cell lymphoma (PTCL) data presented at the 2025 ASH Annual Meeting and Exposition. They discuss emerging agents, novel combinations, and ongoing trials with potential clinical relevance. Foss and Lunning conclude by outlining key research directions to watch as the PTCL treatment landscape continues to evolve.
Advertisement
Related to this article

The FDA approved a label update for axi-cel, removing its limitations of use for patients with primary central nervous system lymphoma.

Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship Training
Christine Ann Garcia, MD, MPH, discusses error review in fellowship training, survivorship in EGFR+ lung cancer, and nontraditional career paths.

Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.

Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.

The FDA accepted an sNDA for selinexor plus ruxolitinib in myelofibrosis, with a target action date of June 28, 2027.

The FDA has approved neladalkib for previously treated, ALK-positive, locally advanced or metastatic non-small cell lung cancer.

Roswell Park researchers found CD83 CAR T cells could overcome CD19-targeted therapy resistance in preclinical models of B-cell cancers.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
4
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
5

